[1]杨渝伟,黄玉霞,陈小红,等.胱抑素C及其eGFR方程在诊断肝硬化患者肾损害中的应用[J].现代检验医学杂志,2016,31(04):24-29.[doi:10.3969/j.issn.16717-414.2016.04.006]
　YANG Yu-wei,HUANG Yu-xia,CHEN Xiao-hong,et al.Clinical Application of Cystatin C and It's eGFR Equation for Diagnosing Kidney Injure in Patients with Liver Cirrhosis[J].Journal of Modern Laboratory Medicine,2016,31(04):24-29.[doi:10.3969/j.issn.16717-414.2016.04.006]
点击复制

胱抑素C及其eGFR方程在诊断肝硬化患者肾损害中的应用()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年04期
页码:
24-29
栏目:
论著
出版日期:
2016-08-10

文章信息/Info

Title:
Clinical Application of Cystatin C and It's eGFR Equation for Diagnosing Kidney Injure in Patients with Liver Cirrhosis
文章编号:
1671-7414(2016)04-024-06
作者:
杨渝伟1; 黄玉霞2; 陈小红1; 俸家富1
1.绵阳市中心医院检验科,四川绵阳 621000;
2.四川省骨科医院检验科,成都 610041
Author(s):
YANG Yu-wei1; HUANG Yu-xia2; CHEN Xiao-hong1; FENG Jia-fu1
1.Department of Clinical Laboratory,Mianyang Central Hospital,Sichuan Mianyang 621000,China;
2.Department of Clinical Laboratory,Sichuan Orthopeadic Hospital,Chengdu 610041,China
关键词:
肝硬化;  肾功能损害;  估计肾小球滤过率;  胱抑素C;  肌酐
分类号:
R575.2; R446.112
DOI:
10.3969/j.issn.16717-414.2016.04.006
文献标志码:
A
摘要:
目的 探讨血清胱抑素C(cystatin C,CysC)及其估算肾小球滤过率(estimated glomerular filtration rate,eGFR)方程在肝硬化患者肾功能损害中的诊断价值。方法 随机抽取2012年8月～2014年12月间来绵阳市中心医院就诊的肝硬化患者465例,检测其血清肌酐(serum creatinine,SCr)和CysC水平,并采用适用于中国人群的方程计算其相应的eGFR,即eGFRSCr和eGFRCysC。继而用ROC曲线分析此四个标志物对肝硬化患者继发肾功能损害的诊断性能,并与SCr和CysC参考值上限(upper reference limit,UPL)及eGFR医学决定水平(medicine decide level,MDL)作为判断界点进行比较。结果 SCr(男/女),CysC,eGFRSCr和eGFRCysC对肝硬化患者肾功能损害的最佳判断线分别是76.8 μmol/L(男),62.6μmol/L(女),1.24 mg/L,109.9 ml/min/1.73m2和63.4 ml/min/1.73 m2; ROC曲线分析显示,CysC及其eGFRCysC的AUC均高于SCr及其eGFRSCr的AUC(z=3.660～5.387,P<0.001); 比较四者在最佳判断线和UPL/MDL两个判断界点间的诊断性能,在肝硬化及其Child-Pugh分级患者各组中,仅eGFRCysC的敏感度、误诊率和临床诊断一致性均相接近(除误诊率外,P>0.05)。结论 eGFRCysC对肝硬化患者继发肾功能损害的诊断性能优于CysC,SCr和eGFRSCr。但因其并非实测,故各实验室应建立自己的最佳判断线。临床医生应用eGFR评价受试者肾功能,而非局限于其分析物浓度。
Abstract:
Objective To investigate the diagnostic efficiency of Cystatin C(CysC)and it's eGFR equation for diagnosis of kidney impairment in patients with liver cirrhosis.Methods A total of 465 liver cirrhosis patients were enrolled in this study,which admitted to Mianyang Central Hospital between Aug.2012 to Dec.2014.Serum creatinine(SCr)andCysC level were determined,and to be used to calculate their corresponding estimated glomerular filtration rate(eGFR)by the equations suitable for chinese patients,namely eGFRSCr and eGFRCysC.The performance of these fourmarkers to diagnose kidney impairment in liver cirrhosis patients were analyzedby ROC curve method,and to compare with those when the upper reference limits(UPL)of SCr and CysC,and the medicine decide level(MDL)of eGFR,as a threshold.Results The optimal cut-off values of SCr(male or female),CysC,eGFRSCr and eGFRCysC for diagnosing kidney impairment in liver cirrhosis patients were 76.8 μmol/L(male),62.6 μmol/L(female),1.24 mg/L,109.9 ml/min/1.73 m2 and 63.4 ml/min/1.73 m2,respectively.The AUC of both CysC and eGFRCysC were higher than SCr or eGFRSCr(z=3.660～5.387,P<0.001).Comparing the performance of the four on the two thresholds of optimal cut-off value and UPL/MDL,only eGFRCysC,it wassensitivity,misdiagnosis rate and consistency were similar to each other(except misdiagnosis rate,P>0.05),whether in patientswith cirrhosis or varioussubgroups by Child-Pugh classifications.Conclusion eGFRCysC was a better marker than CysC,SCr and eGFRSCr for diagnosingsecondary kidney impairment in patients with cirrhosis.Due to not measurements,each clinical laboratory should establish its own optimal cut-off values.Clinicians should assess renal function with eGFR rather than the concentration ofan analytes.

参考文献/References:

[1] Li X,Wang XK,Chen B,et al.Computational hemodynamics of portal vein hypertension in hepatic cirrhosis patients[J].Biomed Mater Eng,2015,26(Suppl 1):S233-S243.
[2] Rognant N,Lemoine S.Evaluation of renal function in patients with cirrhosis:where are we now[J].World J Gastroenterol,2014,20(10):2533-2541.
[3] Risr LM,Bendtsen F,Mller S.Immunologic,he-modynamic,and adrenalincompetence in cirrhosis:impact on renal dysfunction[J].Hepatol Int,2015,9(1):17-27.
[4] Mller S,Krag A,Bendtsen F.Kidney injury in cirrhosis:pathophysiological and therapeutic aspects of hepatorenal syndromes[J].Liver Int,2014,34(8):1153-1163.
[5] Kidney Disease:Improving Global Outcomes(KDIG O)Acute Kidney Injury Work Group.KDIGO clinical practice guideline for acute kidney injury[J].KidneyInt Suppl,2012,2(1):1-138.
[6] KDOQI 2012 Clinical Practice Guidelines for the Evaluation and Managementof Chronic Kidney Disease[J].Kidney Int Suppl,2013,3(1):1-150.
[7] Beben T,Rifkin DE.GFR Estimating equations and liver disease[J].AdvChronic Kidney Dis,2015,22(5):337-342.
[8] Adebisi SA.Routine reporting of estimated glomerular filtration rate(eGFR)in african laboratories and the need for its increased utilisation in clinical practice[J].Niger Postgrad Med J,2013,20(1):57-62.
[9] Runyon BA.Management of adult patients with ascites due to cirrhosis:update 2012[J].Hepatology,2013,53(1):1-27.
[10] Feng JF,Qiu L,Zhang L,et al.Multicenter study of creatinineand/or cystatin C-based equations for estimation of glomerular filtration rates in Chinese patients with chronic kidney disease[J].PLoS One,2013,8(3):e57240.
[11] Ma YC,Zuo L,Chen JH,et al.Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease[J].J Am Soc Nephrol,2006,17(10):2937-2944.
[12] Allegretti AS,Ortiz G,Wenger J,et al.Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis:a prospective cohort study[J].Int J Nephrol,2015(2015):108139.
[13] Belcher JM.Acute kidney injury in liver disease:ro-le of biomarkers[J].Adv Chronic Kidney Dis,2015,22(5):368-375.
[14] Drion I,Cobbaert C,Groenier KH,et al.Clinical evaluation of analytical variations in serum creatinine measurements:why laboratories should abandonjaffe techniques[J].Bmc Nephrol,2012,13(10):133.
[15] C'ulafic' D,(ˇoverS)tulic' M,Obrenovi R,et al.Role of cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis[J].World J Gastroenterol,2014,20(21):6573-6579.
[16] Kim DJ,Kang HS,Choi HS,et al.Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels[J].Korean J Hepatol,2011,17(2):130-138.
[17] Lamb EJ,Stevens PE.Estimating and measuring gl-omerular filtration rate:methods of measurement and markers for estimation[J].Curr Opin Nephrol Hypertens,2014,23(3):258-266.
[18] Florkowski CM,Chew-Harris JS.Methods of estimating GFR-different equations including CKD-EPI[J].Clin Biochem Rev,2011,32(2):75-79.
[19] Mindikoglu AL,Dowling TC,Weir MR,et al.Performance of chronic kidneydisease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis[J].Hepatology,2014,59(4):1532-1542.
[20] Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L,et al.Estimatedglomerular filtration rate(eGFR)values as predictor of renal insufficiency inadvanced stages of liver diseases with different etiology[J].Med Arh,2014,68(3):159-162.
[21] Uguen T,Jezequel C,Ropert M,et al.Pretransplant renal function according to CKD-EPI cystatin C equation is a prognostic factor of death after livertransplantation[J].Liver Int,2016,36(4):547-554.
[22] Cholongitas E,Arsos G,Goulis J,et al.Glomerular filtration rate is an independent factor of mortality in patients with decompensated cirrhosis[J].Hepatol Res,2014,44(10):E145-E155.
[23] 张志明,张蓬杰.血肌酐、胱抑素C、简化MDRD和LeBricon公式在评估肾移植术后肾功能中的作用[J].现代检验医学杂志,2014,29(5):97-99,103. Zhang ZM,Zhang PJ.Role of serum creatinine,cy-statin C,abbreviated MDRD and le bricon formula in the evaluation of renal function after renal transplantation[J].Journal of Modern Laboratory Medicine,2014,29(5):97-99,103.

相似文献/References:

[1]杨渝伟,陈小红,胡 冬,等.血清中性粒细胞明胶酶相关脂质运载蛋白水平与卒中发生及患者肾功能损害的关系[J].现代检验医学杂志,2018,33(02):23.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　YANG Yu-wei,CHEN Xiao-hong,HU Dong,et al.Relationship of Serum Neutrophil Gelatinase-associated Lipocalin Levels with Stroke Attack and Renal Dysfunction in Patients[J].Journal of Modern Laboratory Medicine,2018,33(04):23.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[2]薛 姣,肖海峰,姜南艳,等.肝硬化患者血浆胆碱酯酶活性对麻醉剂米库氯铵代谢的影响[J].现代检验医学杂志,2019,34(05):124.[doi:10.3969/j.issn.1671-7414.2019.05.030]
　XUE Jiao,XIAO Hai-feng,JIANG Nan-yan,et al.Effects of Plasma Cholinesterase Activity on the Metabolism of Mivacurium(Anesthetic)in Patients with Hepatocirrhosis[J].Journal of Modern Laboratory Medicine,2019,34(04):124.[doi:10.3969/j.issn.1671-7414.2019.05.030]
[3]刘昌贺,李　衡,徐圣杰,等.肝硬化伴肝性脑病与血清IL-6表达水平相关性的meta分析[J].现代检验医学杂志,2022,37(03):56.[doi:10.3969/j.issn.1671-7414.2022.03.012]
　LIU Chang-he,LI Heng,XU Sheng-jie,et al.Meta Analysis of the Correlation between Serum Interleukin-6 and Hepatic Encephalopathy in Liver Cirrhosis[J].Journal of Modern Laboratory Medicine,2022,37(04):56.[doi:10.3969/j.issn.1671-7414.2022.03.012]
[4]赵佳慧,余 雯.乙型肝炎肝硬化患者血清miR-25-3p 和IBSP 表达及临床意义[J].现代检验医学杂志,2022,37(04):96.[doi:10.3969/j.issn.1671-7414.2022.04.019]
　ZHAO Jia-hui,YU Wen.Expression and Clinical Significance of Serum miR-25-3p and IBSP in Patients with Hepatitis B Cirrhosis[J].Journal of Modern Laboratory Medicine,2022,37(04):96.[doi:10.3969/j.issn.1671-7414.2022.04.019]
[5]冯 瑾,魏绪仓.肝硬化患者骨髓造血系统异常的机制研究进展及其骨髓细胞学检查的临床意义[J].现代检验医学杂志,2023,38(02):200.[doi:10.3969/j.issn.1671-7414.2023.02.038 ]
　FENG Jin,WEI Xu-cang.Research Progress on the Mechanism of Bone Marrow Hematopoietic System Abnormalities in Patients with Liver Cirrhosis and Its Clinical Significance of Bone Marrow Cytology[J].Journal of Modern Laboratory Medicine,2023,38(04):200.[doi:10.3969/j.issn.1671-7414.2023.02.038 ]
[6]武 倩,李 英,马燕粉,等.丙型肝炎肝硬化患者进展为肝细胞肝癌预测模型建立及验证[J].现代检验医学杂志,2024,39(05):6.[doi:10.3969/j.issn.1671-7414.2024.05.002]
　WU Qian,LI Ying,MA Yanfen,et al.Establishment and Validation of Prediction Model for Hepatocellular Carcinoma Progression in Patients with Hepatitis C Cirrhosis[J].Journal of Modern Laboratory Medicine,2024,39(04):6.[doi:10.3969/j.issn.1671-7414.2024.05.002]

备注/Memo

备注/Memo:
基金项目:四川省科技厅支撑计划(2009SZ0066),四川省卫生厅科学研究基金(020089),四川省卫计委科研课题(150175)。
作者简介:杨渝伟(1972-),男,大学本科,副主任技师,从事医学检验工作,Tel:13890158866,E-mail:yyw318@vip.163.com。
通讯作者:俸家富,男,主任技师,硕士,研究生导师,E-mail:jiafufeng@aliyun.com。
更新日期/Last Update: 2016-08-10